TuHURA Biosciences (HURA) 10-K2023 FY Annual report

Filed: 18 Sep 23, 4:25pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: appellate, bore, effectuate, electroporation, fall, Favorito, immunology, judgement, kinase, Mirai, NMPA, OTCQX, paused, Pfizer, preemptive, preserve, regenerative, restarted, space, stay, stockover, tyrosine, unrest, Zevra

Removed: AACR, accounted, al, amortization, Anderson, articling, ASX, cancelled, capitalization, cardiovascular, ceased, Celldex, center, centered, cerebral, CFDA, chemoradiation, CI, closure, communicable, complexity, comprising, conclude, contracting, correction, correlate, CSF, cutaneously, CXSP, daily, de, delivered, description, Diploma, divided, driven, economy, emerge, encouraging, Epizyme, explore, fluid, forcing, forfeited, fourteen, Fraser, geography, Guangzhou, heightened, Identifier, ImmunoCellular, ImmunoGen, inactivated, Incyte, infected, Infinity, Inflazyme, initiated, integrated, interval, investigate, irradiation, John, joining, kidney, leader, lieu, liver, LJPC, MD, merge, Merrimack, mOS, MTD, multicenter, Murphy, negotiated, NeuroOncology, novo, Onconova, OS, outbreak, pandemic, PFS, Pharmacokinetic, plasma, platinum, preventative, prolonged, promissory, proposal, protective, Pt, Pulmonary, Puma, RANO, ratio, recession, recurred, Reorganization, REPROVe, retention, Rindopepimut, Simon, simplify, spinal, strain, studying, Sun, surfaced, surviving, SYSUCC, Tanguturi, tolerability, tolerated, travel, treasury, Vulnerable, Waterhouse, Wuhan, XRT, Zarrabian

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

HURA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Independent Registered Public Accounting Firm’s Consent

We consent to the incorporation by reference in the Registration Statement of Kintara Therapeutics, Inc. on Post-Effective Amendment No.1 to Form S-1 [File Nos. 333-232332 and 333-232931], Forms S-3 [File Nos. 333-254662, 333-249675,333-229020 and 333-213600] and Forms S-8 [Files Nos. 333-267631, 333-259858 and 333-248928] of our report dated September 18, 2023, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Kintara Therapeutics, Inc. as of June 30, 2023 and for each of the two years in the period ended June 30, 2023, which report is included in this Annual Report on Form 10-K of Kintara Therapeutics, Inc. for the year ended June 30, 2023.

/s/ Marcum llp

Marcum llp

San Francisco, CA

September 18, 2023